Pharmaceutical Technology Europe-03-01-2004

Pharmaceutical Technology Europe

Selecting Lactose for a Capsule-Based Dry Powder Inhaler

April 01, 2004

Features

16

3

Dry powder inhalers are a well-accepted dosage form for pulmonary drug delivery and a wide variety are either currently available or in development. This article examines a premetered, capsule-based multidose inhaler for which different qualities of a-lactose monohydrate were screened.

Quality Systems for the 21st Century: Process Analytical Technology

March 01, 2004

Features

16

3

Following the launch of its initiative, "Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach," FDA has been looking to process analytical technology (PAT) for improvements in process efficiency and quality. This article discusses the implementation of PAT systems into production environments, its impact on quality assurance and the necessity of an integrated approach. Options for implementing PAT are also presented.

A New Model of an Old Parallelogram

March 01, 2004

Features

16

3

The parallel importing battle continues between wholesalers and manufacturers. The two sides are slugging it out across member states, the courts and even in the streets of Brussels. The EU, meanwhile, has done what it does best - bury its head in the sand and hope that the whole thing blows over.

The Relationship between Saturated Hydrogen Peroxide, Water Vapour and Temperature

March 01, 2004

Features

16

3

Hydrogen peroxide has become the compound of choice for gaseous biodecontamination in the pharmaceutical industry. As some processes operate at vapour concentrations below the dew point, to avoid condensation, and others actually form dew, it is important to understand the relationship between the vapours and to have a method of establishing the dew point.

Certificates of Test - What are the European GMP Requirements?

March 01, 2004

Features

16

3

This article examines European differences in GMP requirements for the acceptance of Certificates of Tests. The authors look at how pharmaceutical manufacturers can address the issues and suggest a US-compatible framework for GMPs that could be incorporated into EU requirements.